Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats

Autores
Albarellos, G. A.; Montoya, L.; Landoni, Maria Fabiana
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg, intravenously (IV)), base (10 mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg, orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)(0-∞) 2.61 ± 1.52 µg.h/mL; volume of distribution (Vz) 2.34±1.76 L/kg; total body clearance (Clt) 2.10±1.37 L/h.kg; elimination half-life (t½λ) 0.75±0.09 h and mean residence time (MRT) 0.88±0.13 h. After intramuscular administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (Cmax), 3.54±2.16 µg/mL; time of peak (Tmax), 1.22±0.67 h; t½λ, 1.94±0.21 h and MRT, 3.50±0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not produce measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)90=0.5 µg/mL for 7 and 1.5 h, respectively. However, these results should be cautiously interpreted since tissue erythromycin concentrations have not been measured and, it is recognised that they can reach much higher concentrations than in blood, correlating better with clinical efficacy.
Fil: Albarellos, G. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Montoya, L.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Landoni, Maria Fabiana. Universidad Nacional de La Plata; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
Materia
ANTIBIOTICS
ANTIMICROBIALS
CATS
ERYTHROMYCIN
MACROLIDES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/193603
Acceder
id CONICETDig_813e4f86053900d2b7f13efac96b6093
oai_identifier_str oai:ri.conicet.gov.ar:11336/193603
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to catsAlbarellos, G. A.Montoya, L.Landoni, Maria FabianaANTIBIOTICSANTIMICROBIALSCATSERYTHROMYCINMACROLIDEShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg, intravenously (IV)), base (10 mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg, orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)(0-∞) 2.61 ± 1.52 µg.h/mL; volume of distribution (Vz) 2.34±1.76 L/kg; total body clearance (Clt) 2.10±1.37 L/h.kg; elimination half-life (t½λ) 0.75±0.09 h and mean residence time (MRT) 0.88±0.13 h. After intramuscular administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (Cmax), 3.54±2.16 µg/mL; time of peak (Tmax), 1.22±0.67 h; t½λ, 1.94±0.21 h and MRT, 3.50±0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not produce measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)90=0.5 µg/mL for 7 and 1.5 h, respectively. However, these results should be cautiously interpreted since tissue erythromycin concentrations have not been measured and, it is recognised that they can reach much higher concentrations than in blood, correlating better with clinical efficacy.Fil: Albarellos, G. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Montoya, L.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Landoni, Maria Fabiana. Universidad Nacional de La Plata; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaElsevier2011-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/193603Albarellos, G. A.; Montoya, L.; Landoni, Maria Fabiana; Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats; Elsevier; The Veterinary Journal; 187; 1; 1-2011; 129-1321090-0233CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1090023309003840info:eu-repo/semantics/altIdentifier/doi/10.1016/j.tvjl.2009.09.019info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:07:10Zoai:ri.conicet.gov.ar:11336/193603instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:07:10.974CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
title Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
spellingShingle Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
Albarellos, G. A.
ANTIBIOTICS
ANTIMICROBIALS
CATS
ERYTHROMYCIN
MACROLIDES
title_short Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
title_full Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
title_fullStr Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
title_full_unstemmed Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
title_sort Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats
dc.creator.none.fl_str_mv Albarellos, G. A.
Montoya, L.
Landoni, Maria Fabiana
author Albarellos, G. A.
author_facet Albarellos, G. A.
Montoya, L.
Landoni, Maria Fabiana
author_role author
author2 Montoya, L.
Landoni, Maria Fabiana
author2_role author
author
dc.subject.none.fl_str_mv ANTIBIOTICS
ANTIMICROBIALS
CATS
ERYTHROMYCIN
MACROLIDES
topic ANTIBIOTICS
ANTIMICROBIALS
CATS
ERYTHROMYCIN
MACROLIDES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg, intravenously (IV)), base (10 mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg, orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)(0-∞) 2.61 ± 1.52 µg.h/mL; volume of distribution (Vz) 2.34±1.76 L/kg; total body clearance (Clt) 2.10±1.37 L/h.kg; elimination half-life (t½λ) 0.75±0.09 h and mean residence time (MRT) 0.88±0.13 h. After intramuscular administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (Cmax), 3.54±2.16 µg/mL; time of peak (Tmax), 1.22±0.67 h; t½λ, 1.94±0.21 h and MRT, 3.50±0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not produce measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)90=0.5 µg/mL for 7 and 1.5 h, respectively. However, these results should be cautiously interpreted since tissue erythromycin concentrations have not been measured and, it is recognised that they can reach much higher concentrations than in blood, correlating better with clinical efficacy.
Fil: Albarellos, G. A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Montoya, L.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Landoni, Maria Fabiana. Universidad Nacional de La Plata; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
description The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg, intravenously (IV)), base (10 mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg, orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)(0-∞) 2.61 ± 1.52 µg.h/mL; volume of distribution (Vz) 2.34±1.76 L/kg; total body clearance (Clt) 2.10±1.37 L/h.kg; elimination half-life (t½λ) 0.75±0.09 h and mean residence time (MRT) 0.88±0.13 h. After intramuscular administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (Cmax), 3.54±2.16 µg/mL; time of peak (Tmax), 1.22±0.67 h; t½λ, 1.94±0.21 h and MRT, 3.50±0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not produce measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)90=0.5 µg/mL for 7 and 1.5 h, respectively. However, these results should be cautiously interpreted since tissue erythromycin concentrations have not been measured and, it is recognised that they can reach much higher concentrations than in blood, correlating better with clinical efficacy.
publishDate 2011
dc.date.none.fl_str_mv 2011-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/193603
Albarellos, G. A.; Montoya, L.; Landoni, Maria Fabiana; Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats; Elsevier; The Veterinary Journal; 187; 1; 1-2011; 129-132
1090-0233
CONICET Digital
CONICET
url http://hdl.handle.net/11336/193603
identifier_str_mv Albarellos, G. A.; Montoya, L.; Landoni, Maria Fabiana; Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats; Elsevier; The Veterinary Journal; 187; 1; 1-2011; 129-132
1090-0233
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1090023309003840
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.tvjl.2009.09.019
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269992494563328
score 13.13397

Publicaciones similares